Take action, page-95

Turtlespeed, two very different journeys when comparing your above article and IBX.

Firstly, our type of Iron oxide nanoparticles are and have been used successfully in humans,
i.e. for the treatment of conditions such as Anemia.
The purpose of Phase 1 trials is to identify if there are any adverse reactions to IBX's SPIONs.

The next important component of the trial is to test the efficacy. IBX SPIONs are going to be
competing with things like Gadolinium, (the next best available FDA approved product).
Regarding the MRI component of your article, IBX SPIONs have already been proven to be
the best for low field MRI (as proven in a study done by the University of Sydney).

We are a long way further down the road than our nearest competitor; and with CSIRO
funding to one-day fast-track preclinical research between IBX and Monash University
with the aim of achieving proof of concept in the validation of MagSense prostate cancer
imaging agent together with our $2.6M R&D grant for collaboration work with Patrys (PAB)
for the purpose of improving brain tumour imaging and diagnostics you can see that our
paths when compared to the research undertaken with your above post article and IBX
are vastly different.
Your above article talks about the research "playing a vital role in increased diagnosis
of cerebro-cardio diseases such as stroke, myocardial infarction, angina, and dementia."

Anyway, not every stock is for every investor and what is for sure is that sentiment is unlikely
to stay unchanged.
Were all mindful of the narrative/expectations and the reality so far this year, however, Q4 and
onwards has the potential to change all of that and the main catalyst is the soon to be four
clinical sites in three different states working together in achieving screening and recruitment
for our trial. Once this is achieved the bemoaning of the lack of recruitment numbers will
cease and the tech will have the chance to finally speak for itself.